BEIGENE, LTD. (NASDAQ:BGNE) Files An 8-K Other Events
Item 8.01 Other Events.
BeiGene,Ltd. (the Company) is providing certain business updates
in the materials attached as Exhibit99.1 to this Current Report
on Form8-K and incorporated by reference herein.
Item9.01 Financial Statements and
Exhibits.
(d) Exhibits.
|
ExhibitNo. |
|
Description |
|
99.1 |
BeiGene,Ltd. materials dated November2016 |
About BEIGENE, LTD. (NASDAQ:BGNE)
BeiGene, Ltd. is a biopharmaceutical company. The Company is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. It is developing its product candidate, BGB-3111, a potent and selective small molecule Bruton’s tyrosine kinase (BTK) inhibitor, as a monotherapy and in combination with other therapies for the treatment of a range of lymphomas. It is developing its product candidate, BGB-A317, a humanized monoclonal antibody against the immune checkpoint receptor programmed cell death protein 1 (PD-1), as a monotherapy and as a combination agent for various solid-organ and blood-borne cancers. It is developing BGB-290, a molecularly targeted, orally available, potent and selective inhibitor of poly ADP ribose polymerase 1 (PARP1) and PARP2, as a monotherapy and in combination with other therapies for the treatment of homologous recombination deficient cancers. It is also developing BGB-283 for the treatment of cancers. BEIGENE, LTD. (NASDAQ:BGNE) Recent Trading Information
BEIGENE, LTD. (NASDAQ:BGNE) closed its last trading session up +0.59 at 36.90 with 60,375 shares trading hands.